Faster drug discovery leveraging digital human twin and quantum technology
Cost:
Reduced R&D costs at the pre-clinical stage
Speed:
Accelerated drug discovery and faster drugs from lab to counter
Quality:
Improved efficiency and effectiveness of drug development
Compliance:
Fully regulatory compliant with CDISC SEND standards
Driving research and pre-clinical studies leveraging HPC & QLM
Target identification and validation is too slow using traditional means of drug discovery. Atos provides the compute power and expertise to convert sequencing data and 3D-EM to actionable insights, followed by pre-clinical studies on human digital twin.
Atos can help in the complete value chain from research to pre-clincal studies and submission of SEND data for regulatory approval.
Advanced Computing
- Simplify workflows by processing data at the edge
- Deliver secure insights from IOT data in near real-time
- Federated learning platforms to create a collaborative eco system
- Data analytics capabilities that grow seamlessly
- Explore new hypotheses with Atos quantum computing simulator
Contact us to learn more about our Advanced Computing solutions >
Data intelligence
- Services to exchange, integrate and analyze the vast amounts of data collected from different sources into a global information infrastructure
- Sensors network to gather different physiological and environmental / localisation data
- Clinical decision support systems (CDSS)
- Algorithms to model data and simulate physiological behavior
Contact us to learn more about our Data intelligence solutions >
Simulation
Simulation capabilities for molecular modeling and protein folding to accelerate drug discovery
SEND support services
- SEND consulting
- SEND data conversion
- Data validation
- Migration services
- Compliance services
- Labeling
Find out more
Atos SEND services
How to ensure submission-ready SEND data sets from any data source.
Omics – the revolution of P4 medicine
There is a significant gap between the worlds of cutting-edge genomic research (bench) and everyday healthcare (bedside). To fill this gap, an active process of genomics translation is necessary.
Key contacts
Harbir Sawhney
Global Portfolio Head, Healthcare and Life Sciences
Gauri Deshmukh
Senior Consultant, Life Sciences